Cardio Diagnostics Holdings, Inc. continues to develop and commercialize epigenetics-based cardiovascular diagnostic tests leveraging its proprietary AI-driven Multi-Omics Engine™, targeting coronary heart disease and other conditions. Despite securing CPT PLA codes and CMS gapfill pricing for its tests, the company’s revenue remains minimal with substantial operating losses, reflecting typical prolonged commercialization cycles in molecular diagnostics. Cardio faces significant risks, including Nasdaq listing challenges due to low market value and the inherent uncertainties in regulatory approval, reimbursement expansion, and clinical adoption. Growth hinges on expanding payer coverage, broadening clinical evidence, strategic partnerships, and international market penetration.